Effect of moderate restriction diet in treatment of non-alcoholic fatty liver disease

The effect of moderate carbohyderate restriction diet on liver enzymes, steatosis and fibrosis in normal weight individuals with non-alcoholic fatty liver disease: a parallel randomized controlled clinical trials

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210119050086N1

Enrollment

Registered

2021-02-20

Start date

2021-11-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Intake of moderate carbohydrate restriction diet, which included 40-45% of energy from carbohydrates, 35-40% of energy from fat, and the rest of energy from a sourc

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Body mass index 18.5-25 kg/m2 Age range 18-65 years Patients with non-alcoholic fatty liver disease

Exclusion criteria

Exclusion criteria: Alcohol consumption Pregnancy or breastfeeding Suffering from other liver diseases Consuming corticosteroids during the last three months Drugs or tobacco use Follow a weight loss diet during the last three months

Design outcomes

Primary

Measure	Time frame
Steatosis. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Fibro-scan.;Liver enzyme (ALT, AST and GGT). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.	—

Secondary

Measure	Time frame
Lipid profile (TG, Total cholesterol, LDL-c and LDH-c). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.;Glycemic index (FBS, FBI, HOMA-IR and QUICKI). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.;Weight. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Scales.;Waist circumference. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Tape meter.;Body mass index (BMI). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Formula (weight (kilograms) divided by the squared height (meters)).;Fibrosis. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Fibro-scan.	—

Measure

Time frame

Lipid profile (TG, Total cholesterol, LDL-c and LDH-c). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.;Glycemic index (FBS, FBI, HOMA-IR and QUICKI). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.;Weight. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Scales.;Waist circumference. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Tape meter.;Body mass index (BMI). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Formula (weight (kilograms) divided by the squared height (meters)).;Fibrosis. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Fibro-scan.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Dashti

Tehran University of Medical Sciences

Fatemehda1996@gmail.com+98 21 8895 5975

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026